Drugs that contain Fentanyl Citrate
1. Drug name - FENTORA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(2 years from now) | |
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(2 years from now) | |
| US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(5 years from now) | |
| US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(5 years from now) | |
Treatment: NA
Dosage: TABLET;BUCCAL, SUBLINGUAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.1MG BASE | TABLET;BUCCAL, SUBLINGUAL | Prescription |
| EQ 0.2MG BASE | TABLET;BUCCAL, SUBLINGUAL | Prescription |
| EQ 0.3MG BASE | TABLET;BUCCAL, SUBLINGUAL | Discontinued |
| EQ 0.4MG BASE | TABLET;BUCCAL, SUBLINGUAL | Prescription |
| EQ 0.6MG BASE | TABLET;BUCCAL, SUBLINGUAL | Prescription |
| EQ 0.8MG BASE | TABLET;BUCCAL, SUBLINGUAL | Prescription |
2. Drug name - LAZANDA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(1 year, 3 months from now) | |
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(1 year, 3 months from now) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(1 year, 3 months from now) | |
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(2 years from now) | |
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(9 years from now) | |
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.1MG BASE | SPRAY, METERED;NASAL | Prescription |
| EQ 0.3MG BASE | SPRAY, METERED;NASAL | Discontinued |
| EQ 0.4MG BASE | SPRAY, METERED;NASAL | Prescription |
3. Drug name - ONSOLIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597288 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.2MG BASE | FILM;BUCCAL | Discontinued |
| EQ 0.4MG BASE | FILM;BUCCAL | Discontinued |
| EQ 0.6MG BASE | FILM;BUCCAL | Discontinued |
| EQ 0.8MG BASE | FILM;BUCCAL | Discontinued |
| EQ 1.2MG BASE | FILM;BUCCAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.